Tuberculosis Research and Treatment / 2012 / Article / Tab 1

Clinical Study

The Use of Interferon Gamma Release Assays in the Diagnosis of Active Tuberculosis

Table 1

(a) Median and range for patient age and IGRA test result for all culture positive cases of active tuberculosis, by organ manifestation. (b) Median and range for age and IGRA test result for all controls, by diagnosis. “Others” includes other lung diseases such as asbestosis, aspergillosis, asthma, bronchiectasis, pleural effusion, haemoptysis, fibrosis, and sarcoidosis. (c) Study results for TB cases and controls. ( : sample size, CI: confidence interval).
(a)

MTB infectionMaleFemaleTotalMedian age, years (range)Median QFT, IU/mL (range)

Lung28255345 (4–83)2.40 (0,00–103,4)
Pleura23526 (17–76)2,45 (0,96–300)
Lymph node21365 (25–69)21,32 (3,78–86,8)

Total32296146 (5–84)3.46 (0,00–300)

(b)

DiagnosisMaleFemaleTotalMedian age, years (range)Median QFT, IU/mL (range)

Malignancy22234569 (39–90)0,01 (0,00–23,9)
Bronchitis27134064 (1–90)0,00 (0,00–1,84)
Pneumonia30174767 (1–99)0,00 (0,00–75)
Others534910262,5 (5–99)0,02 (0,00–103,4)

Total13210223466 (1–99)0,00 (0,00–103,4)

(c)

QFTAge
Mean95% CI Mean95% CI

TB6114.133.44–24.82<0.0547.841.88–53.79<0.05
Control2341.330.24–2.436360.56–65.39

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.